​

Aldeyra Therapeutics (ALDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALDX Stock Forecast

Aldeyra Therapeutics (ALDX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $11.00, with a high of $12.00 and a low of $10.00. This represents a 275.43% increase from the last price of $2.93.

$2 $4 $6 $8 $10 $12 High: $12 Avg: $11 Low: $10 Last Closed Price: $2.93

ALDX Stock Rating

Aldeyra Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 19 Strong Sell Sell Hold Buy Strong Buy

ALDX Price Target Upside V Benchmarks

TypeNameUpside
StockAldeyra Therapeutics275.43%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$2.93$2.93$2.93
Upside/Downside--309.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2524---6
May, 2525---7
Apr, 2525---7
Mar, 2526---8
Feb, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 03, 2024Justin KimOppenheimer$12.00$5.14133.46%309.56%
Apr 03, 2024Justin KimOppenheimer$10.00$3.55181.69%241.30%
Apr 02, 2024Matt CaufieldH.C. Wainwright$10.00$3.27205.81%241.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024OppenheimerOutperformOutperformhold
Apr 03, 2024OppenheimerOutperformupgrade
Jun 09, 2022CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-950K $-750K $-550K $-350K $-150K $50K Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.64$-938.92K----
Avg Forecast$-0.67$-0.91$-0.07$-0.15$1.50$2.50
High Forecast$-0.64$-0.86$0.75$0.13$4.67$7.16
Low Forecast$-0.68$-0.94$-0.38$-0.42$-0.77$0.06
Surprise %-4.48%103177886.81%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast$2.57M$16.50M$83.74M$53.70M$127.70M$193.51M
High Forecast$6.26M$40.14M$203.73M$54.94M$310.68M$470.77M
Low Forecast$640.11K$4.11M$20.85M$52.46M$31.79M$48.17M
Surprise %------

Net Income Forecast

$-60T $-47T $-34T $-21T $-8T $5T Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-37.54M$-55.85T----
Avg Forecast$-39.04M$-52.84M$-4.59M$-14.47M$28.99M$147.36M
High Forecast$-37.75M$-50.52M$43.97M$7.81M$275.53M$421.83M
Low Forecast$-40.33M$-55.16M$-22.65M$-24.65M$-45.24M$3.48M
Surprise %-3.84%105700981.25%----

ALDX Forecast FAQ

Is Aldeyra Therapeutics stock a buy?

Aldeyra Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aldeyra Therapeutics is a favorable investment for most analysts.

What is Aldeyra Therapeutics's price target?

Aldeyra Therapeutics's price target, set by 19 Wall Street analysts, averages $11 over the next 12 months. The price target range spans from $10 at the low end to $12 at the high end, suggesting a potential 275.43% change from the previous closing price of $2.93.

How does Aldeyra Therapeutics stock forecast compare to its benchmarks?

Aldeyra Therapeutics's stock forecast shows a 275.43% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Aldeyra Therapeutics over the past three months?

  • June 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aldeyra Therapeutics’s EPS forecast?

Aldeyra Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.07, marking a -100.00% decrease from the reported $-939K in 2024. Estimates for the following years are $-0.15 in 2026, $1.5 in 2027, and $2.5 in 2028.

What is Aldeyra Therapeutics’s revenue forecast?

Aldeyra Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $83.74M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $53.7M, followed by $127.7M for 2027, and $193.51M for 2028.

What is Aldeyra Therapeutics’s net income forecast?

Aldeyra Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-4.594M, representing a -100.00% decrease from the reported $-55.851T in 2024. Projections indicate $-14.473M in 2026, $28.99M in 2027, and $147.36M in 2028.